摘要
目的:分析活动期炎症性肠病患者采取美沙拉嗪联合安肠愈疡汤加味治疗的临床应用价值。方法:此次研究选取2018年7月-2019年7月我院住院和门诊随机混合确诊为活动期炎症性肠病患者90例作为观察目标,根据时间先后分为观察组与对照组,对照组患者单纯以美沙拉嗪药物治疗,观察组患者采取美沙拉嗪联合安肠愈疡汤加味治疗,对比两组治疗效果,评估两组患者治疗前后中医证候评分差异,检验并对比各组患者治疗前后淋巴细胞亚群指标及炎症因子水平,同时比较两组患者治疗后肠镜下表现。结果:观察组治疗总疗效明显优于对照组(P<0.05)。两组患者未经治疗前,中医证候各项评分、淋巴细胞亚群指标、炎症因子水平等均无明显差异(P>0.05),经一段时间治疗后,观察组患者肠镜下表现与对照组无明显差异(P>0.05),观察组患者中医证候各项评分均明显低于对照组(P<0.05),同时淋巴细胞亚群各项指标均高于对照组,炎症因子水平均低于对照组(P<0.05)。结论:活动期炎症性肠病患者采取美沙拉嗪联合安肠愈疡汤加味治疗效果更佳,可改善患者症状表现,提高免疫功能,减少炎症因子水平,改善肠镜下表现,值得大力推广应用。
Objective:To analyze the clinical efficacy of mesalazine with the Anchang Yuyang decoction(安肠愈疡汤)on inflammatory bowel disease in active stage.Methods:90 patients were randomly divided into the observation group and control group.The control group took mesalazine,and the observation group was treated with the Anchang Yuyang decoction more.Results:The total efficiency in the observation group was significantly better than the control group(P<0.05).After a period of treatment,colonoscopy performance between two groups showed no significant difference(P>0.05).The scores of TCM symptoms in the observation group were significantly lower than those in the control group(P<0.05).The indicators of lymphocyte subsets were higher than those in the control group,and the levels of inflammatory factors were lower than those in the control group(P<0.05).Conclusion:Mesalazine with the Anchang Yuyang decoction can improve symptom,immune function,and reduce the level of inflammatory factors,and improve the performance under the colonoscopy.It is worth promoting vigorously.
出处
《中医临床研究》
2020年第14期60-62,共3页
Clinical Journal Of Chinese Medicine
关键词
安肠愈疡汤
美沙拉嗪
活动期炎症性肠病
免疫功能
The Anchang Yuyang decoction
Mesalazine
Active inflammatory bowel disease
Immune function
